Resistance determinants and clonal diversity in group A streptococci collected during a period of increasing macrolide resistance

Stefania Cresti, Maria Lattanzi, Alessandra Zanchi, Francesca Montagnani, Simona Pollini, Carla Cellesi, Gian Maria Rossolini

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Susceptibility to macrolides and lincosamides was investigated with 299 consecutive nonduplicate Streptococcus pyogenes clinical isolates collected over a 6-year period (1992 to 1997) from an area of central Italy. During this period, macrolide resistance rates steadily increased (from 9% in 1992 to 53% in 1997; P <0.001). The increase was caused by isolates with a macrolide-lincosamide-streptogramin B resistance phenotype, carrying mostly erm(B) but also erm(TR) genes, that were not detected in the first 2 years and were detected with increasing prevalence (8, 5, 26, and 37%, respectively) during the following 4 years. During the same period, the prevalence of isolates with a macrolide resistance phenotype, carrying mef(A) determinants, did not vary significantly; on average it was 13%, with modest rate fluctuations in different years and no definite trend. Molecular typing revealed a remarkable clonal diversity among susceptible and resistant isolates and a notable heterogeneity of the genetic environment of the resistance genes. The analysis of clonal diversity in relation with resistance phenotypes and genotypes revealed that increased macrolide resistance rates were due to a complex interplay of different mechanisms, with a relevant contribution played by an "epidemic" spread of genetic elements carrying the erm(B) gene among the circulating streptococcal population.

Original languageEnglish
Pages (from-to)1816-1822
Number of pages7
JournalAntimicrobial Agents and Chemotherapy
Volume46
Issue number6
DOIs
Publication statusPublished - 2002

Fingerprint

Macrolides
Streptococcus
Lincosamides
Phenotype
Streptogramin B
Genes
Molecular Typing
Genetic Heterogeneity
Streptococcus pyogenes
Italy
Genotype
Population

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Resistance determinants and clonal diversity in group A streptococci collected during a period of increasing macrolide resistance. / Cresti, Stefania; Lattanzi, Maria; Zanchi, Alessandra; Montagnani, Francesca; Pollini, Simona; Cellesi, Carla; Rossolini, Gian Maria.

In: Antimicrobial Agents and Chemotherapy, Vol. 46, No. 6, 2002, p. 1816-1822.

Research output: Contribution to journalArticle

Cresti, Stefania ; Lattanzi, Maria ; Zanchi, Alessandra ; Montagnani, Francesca ; Pollini, Simona ; Cellesi, Carla ; Rossolini, Gian Maria. / Resistance determinants and clonal diversity in group A streptococci collected during a period of increasing macrolide resistance. In: Antimicrobial Agents and Chemotherapy. 2002 ; Vol. 46, No. 6. pp. 1816-1822.
@article{676c8fc7fbe04ff99502594e49db7f18,
title = "Resistance determinants and clonal diversity in group A streptococci collected during a period of increasing macrolide resistance",
abstract = "Susceptibility to macrolides and lincosamides was investigated with 299 consecutive nonduplicate Streptococcus pyogenes clinical isolates collected over a 6-year period (1992 to 1997) from an area of central Italy. During this period, macrolide resistance rates steadily increased (from 9{\%} in 1992 to 53{\%} in 1997; P <0.001). The increase was caused by isolates with a macrolide-lincosamide-streptogramin B resistance phenotype, carrying mostly erm(B) but also erm(TR) genes, that were not detected in the first 2 years and were detected with increasing prevalence (8, 5, 26, and 37{\%}, respectively) during the following 4 years. During the same period, the prevalence of isolates with a macrolide resistance phenotype, carrying mef(A) determinants, did not vary significantly; on average it was 13{\%}, with modest rate fluctuations in different years and no definite trend. Molecular typing revealed a remarkable clonal diversity among susceptible and resistant isolates and a notable heterogeneity of the genetic environment of the resistance genes. The analysis of clonal diversity in relation with resistance phenotypes and genotypes revealed that increased macrolide resistance rates were due to a complex interplay of different mechanisms, with a relevant contribution played by an {"}epidemic{"} spread of genetic elements carrying the erm(B) gene among the circulating streptococcal population.",
author = "Stefania Cresti and Maria Lattanzi and Alessandra Zanchi and Francesca Montagnani and Simona Pollini and Carla Cellesi and Rossolini, {Gian Maria}",
year = "2002",
doi = "10.1128/AAC.46.6.1816-1822.2002",
language = "English",
volume = "46",
pages = "1816--1822",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "6",

}

TY - JOUR

T1 - Resistance determinants and clonal diversity in group A streptococci collected during a period of increasing macrolide resistance

AU - Cresti, Stefania

AU - Lattanzi, Maria

AU - Zanchi, Alessandra

AU - Montagnani, Francesca

AU - Pollini, Simona

AU - Cellesi, Carla

AU - Rossolini, Gian Maria

PY - 2002

Y1 - 2002

N2 - Susceptibility to macrolides and lincosamides was investigated with 299 consecutive nonduplicate Streptococcus pyogenes clinical isolates collected over a 6-year period (1992 to 1997) from an area of central Italy. During this period, macrolide resistance rates steadily increased (from 9% in 1992 to 53% in 1997; P <0.001). The increase was caused by isolates with a macrolide-lincosamide-streptogramin B resistance phenotype, carrying mostly erm(B) but also erm(TR) genes, that were not detected in the first 2 years and were detected with increasing prevalence (8, 5, 26, and 37%, respectively) during the following 4 years. During the same period, the prevalence of isolates with a macrolide resistance phenotype, carrying mef(A) determinants, did not vary significantly; on average it was 13%, with modest rate fluctuations in different years and no definite trend. Molecular typing revealed a remarkable clonal diversity among susceptible and resistant isolates and a notable heterogeneity of the genetic environment of the resistance genes. The analysis of clonal diversity in relation with resistance phenotypes and genotypes revealed that increased macrolide resistance rates were due to a complex interplay of different mechanisms, with a relevant contribution played by an "epidemic" spread of genetic elements carrying the erm(B) gene among the circulating streptococcal population.

AB - Susceptibility to macrolides and lincosamides was investigated with 299 consecutive nonduplicate Streptococcus pyogenes clinical isolates collected over a 6-year period (1992 to 1997) from an area of central Italy. During this period, macrolide resistance rates steadily increased (from 9% in 1992 to 53% in 1997; P <0.001). The increase was caused by isolates with a macrolide-lincosamide-streptogramin B resistance phenotype, carrying mostly erm(B) but also erm(TR) genes, that were not detected in the first 2 years and were detected with increasing prevalence (8, 5, 26, and 37%, respectively) during the following 4 years. During the same period, the prevalence of isolates with a macrolide resistance phenotype, carrying mef(A) determinants, did not vary significantly; on average it was 13%, with modest rate fluctuations in different years and no definite trend. Molecular typing revealed a remarkable clonal diversity among susceptible and resistant isolates and a notable heterogeneity of the genetic environment of the resistance genes. The analysis of clonal diversity in relation with resistance phenotypes and genotypes revealed that increased macrolide resistance rates were due to a complex interplay of different mechanisms, with a relevant contribution played by an "epidemic" spread of genetic elements carrying the erm(B) gene among the circulating streptococcal population.

UR - http://www.scopus.com/inward/record.url?scp=0036090493&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036090493&partnerID=8YFLogxK

U2 - 10.1128/AAC.46.6.1816-1822.2002

DO - 10.1128/AAC.46.6.1816-1822.2002

M3 - Article

C2 - 12019095

AN - SCOPUS:0036090493

VL - 46

SP - 1816

EP - 1822

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 6

ER -